AF
NRIX icon

Allworth Financial’s Nurix Therapeutics NRIX Stock Holding History

Allworth Financial’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.25K Buy
145
+51
+54% +$846 ﹤0.01% 4317
2025
Q4 		$1.78K Buy
94
+10
+12% +$144 ﹤0.01% 4166
2025
Q3 		$777 Buy
+84
New +$872 ﹤0.01% 4319

Other funds holding NRIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

Allworth Financial's NRIX Position: Q1 2026 in Review

Allworth Financial increased its Nurix Therapeutics (NRIX) stake by 54% in Q1 2026, buying an estimated $846 and bringing the position to 145 shares worth $2.25K. The position accounts for ﹤0.01% of the portfolio, ranked #4317.

Allworth Financial first reported a position in NRIX in Q3 2025 and has held it in 3 quarters since. 195 funds tracked by Wall St. Rank hold NRIX as of Q1 2026.

  • Allworth Financial held 145 shares of Nurix Therapeutics worth $2.25K as of Q1 2026.
  • Allworth Financial bought 51 Nurix Therapeutics shares in Q1 2026, an estimated $846.
  • Nurix Therapeutics made up ﹤0.01% of Allworth Financial's portfolio in Q1 2026, its #4317 holding.
  • Allworth Financial first reported a position in Nurix Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • 195 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q1 2026.

Based on Allworth Financial's 13F filing for Q1 2026, filed 15 May 2026.